BRUKINSA™ (zanubrutinib) Approved for the Treatment of Mantle Cell Lymphoma, Available from Onco360

As a specialty pharmacy dedicated to serving people with cancer, Onco360 is pleased to be one of a few pharmacies bringing this new innovative treatment to MCL patients.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, November 21, 2019
Information
Tags: 
Research, FDA, Other Health, Managed care, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, RTT, Medical specialties, Medicine, Cancer, Hematology, Anatomical pathology, Lymphoma, Mantle cell lymphoma, Non-Hodgkin lymphoma, Hodgkin's lymphoma, Lymph node, Marginal zone B-cell lymphoma
Geotags: 
Kentucky, United States
⚠ generated by AI ↴
Organisation: 
ONCO360
Summary
Key Points: 
  • As a specialty pharmacy dedicated to serving people with cancer, Onco360 is pleased to be one of a few pharmacies bringing this new innovative treatment to MCL patients.
  • According to the American Cancer Society , Mantle cell lymphoma is a type of non-Hodgkins lymphoma representing 3-10% of all non-Hodgkins lymphomas in the United States.
  • By the time it is diagnosed, mantle cell lymphoma has usually spread to the lymph nodes, bone marrow and other organs.
  • Across both trials, BRUKINSA achieved an ORR, which is the sum of complete responses and partial responses, of 84%.


Onco360®, the nation’s largest independent Oncology Pharmacy, has been selected by BeiGene to be a specialty pharmacy network partner for BRUKINSA™ (zanubrutinib), a new oral treatment for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

“The approval of BRUKINSA as a second-line therapy option for patients with relapsed and refractory MCL is an important advancement in fighting this devastating disease,” said Paul Jardina, President and CEO, Onco360. “As a specialty pharmacy dedicated to serving people with cancer, Onco360 is pleased to be one of a few pharmacies bringing this new innovative treatment to MCL patients.”

According to the American Cancer Society, Mantle cell lymphoma is a type of non-Hodgkin’s lymphoma representing 3-10% of all non-Hodgkin’s lymphomas in the United States. By the time it is diagnosed, mantle cell lymphoma has usually spread to the lymph nodes, bone marrow and other organs. In relapsed lymphoma, the disease reappears or grows again after a period of remission, while in refractory lymphoma, the disease does not respond to treatment or responds only briefly.

BRUKINSA is manufactured by BeiGene, a global, commercial-stage, research-based biotechnology company, and was approved by the U.S. Food and Drug Administration (FDA) to treat adult patients with MCL on November 14, 2019. The FDA’s approval of BRUKINSA is based on efficacy results from two single-arm clinical trials, with independent review committee (IRC)-assessed ORR per 2014 Lugano Classification as the primary endpoint. Across both trials, BRUKINSA achieved an ORR, which is the sum of complete responses and partial responses, of 84%. For full prescribing information, visit BRUKINSA.com.

About Onco360® Oncology Pharmacy:

Onco360 is the largest independent Oncology Pharmacy and clinical support services company in the country. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, ACHC- JCAHO-, and VIPPS-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Onco360.com.

Copyright: 
Copyright Business Wire 2019